S. Mondkar

Optimization of adenoviral vector-mediated transgene expression in the canine brain in vivo, and in canine glioma cells in vitro.

J. D. Young, C. Barcia, G. Pluhar, 2007, Neuro-oncology.

Herpes Simplex Virus Type 1 Thymidine Kinase Sequence Fused to the lacZ Gene Increases Levels of β-Galactosidase Activity per Genome of High-Capacity but Not First-Generation Adenoviral Vectors In Vitro and In Vivo

Y. Shi, P. Lowenstein, M. Castro, 2008, Journal of Virology.

Flt3L and TK gene therapy eradicate multifocal glioma in a syngeneic glioblastoma model.

C. Barcia, P. Lowenstein, James F Curtin, 2008, Neuro-oncology.

Quantification of high-capacity helper-dependent adenoviral vector genomes in vitro and in vivo, using quantitative TaqMan real-time polymerase chain reaction.

P. Lowenstein, James F Curtin, M. Castro, 2006, Human gene therapy.

One-year expression from high-capacity adenoviral vectors in the brains of animals with pre-existing anti-adenoviral immunity: clinical implications.

C. Barcia, P. Lowenstein, Chunyan Liu, 2007, Molecular therapy : the journal of the American Society of Gene Therapy.

Improved factor VIII variants for gene therapy

C. Barcia, P. Lowenstein, Chunyan Liu, 2022 .

Regulated expression of adenoviral vectors-based gene therapies: therapeutic expression of toxins and immune-modulators.

P. Lowenstein, James F Curtin, Chunyan Liu, 2008, Methods in molecular biology.

Regulatable gene expression systems for gene therapy applications: progress and future challenges.

C. Barcia, P. Lowenstein, James F Curtin, 2005, Molecular therapy : the journal of the American Society of Gene Therapy.

Immunization against the transgene but not the TetON switch reduces expression from gutless adenoviral vectors in the brain.

P. Lowenstein, James F Curtin, Chunyan Liu, 2008, Molecular therapy : the journal of the American Society of Gene Therapy.

ARROW@TU Dublin ARROW@TU Dublin

C. Barcia, James F Curtin, P. Lowenstein, 2022 .